Clinical Trial Update: Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating cannabidiol to reduce cravings in individuals with opioid use disorder on buprenorphine has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• Cannabidiol (cannabidiol)
• buprenorphine (buprenorphine)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Opioid-use Disorder | Phase 2 | Status: COMPLETED | Results posted: 2023-05-18